Evidence map›Paper›PMID 18221909›Full record

ArticleOral oncology2008

CD4+ T helper responses in squamous cell carcinoma of the head and neck.

Kazuaki Chikamatsu, Koichi Sakakura, Takanori Yamamoto, Nobuhiko Furuya, Theresa L Whiteside, Keisuke Masuyama

Abstract readCase Reports
In one paragraph

Article in Oral oncology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Kazuaki ChikamatsuDepartment of Otolaryngology - Head and Neck Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan. chikamatsu@yamanashi.ac.jp
Koichi Sakakura
Takanori Yamamoto
Nobuhiko Furuya
Theresa L Whiteside
Keisuke Masuyama
Gunma University · JPUniversity of Yamanashi Hospital · JPUPMC Hillman Cancer Center · US

Funding

Vaccine Development for Oral CarcinomaP01DE012321 · NIDCR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WHITESIDE, THERESA L. · 1997 to 2006
$6.5M
NIDCR NIH HHS P01 DE012321NIDCR NIH HHS P0-1 DE12321
6 · The paper itself

Abstract

Anti-tumor immunity plays an important role in the development of and protection from malignancy. However, there is a lack of information regarding induction of CD4+ T helper responses in patients with squamous cell carcinoma (SCCHN). To explore anti-tumor immune responses against SCCHN, a permanent cell line, Gun-1 was established from a squamous cell carcinoma of the hypopharynx. In addition to its characterization, we performed mixed lymphocyte-tumor cell cultures (MLTC) using peripheral blood lymphocytes and autologous tumor cells. Furthermore, T cell responses to wild type (wt) p53-derived peptides were assessed. Gun-1 cells overexpressed p53 and were negative for HLA-A2 expression. No tumor-specific or wt p53-specific CD8+ CTL lines could be established from peripheral blood mononuclear cells (PBMCs) of this patient. Autologous tumor-specific HLA-DR-restricted CD4+ T helper clone was obtained by limiting dilutions using bulk populations from MLTC. This clone produced IFN-gamma but not IL-5 in response to autologous tumor cells. In addition, CD4+ T cells were generated from the patient's PBMCs which responded to two HLA-DP5-restricted wt p53-derived peptides. Our results suggest that the immune cells specific for autologous tumor as well as wt p53-derived epitopes are present in the peripheral circulation of this cancer patient. However, helper-type CD4+ T lymphocytes represent the predominant anti-tumor response.

Indexed as

Aged, 80 and overCarcinoma, Squamous CellCD4-Positive T-LymphocytesCytotoxicity, ImmunologicHead and Neck NeoplasmsHumansMaleMutationT-Lymphocytes, CytotoxicTumor Cells, CulturedTumor Suppressor Protein p53Tumor Suppressor Protein p53

Identifiers

PMID18221909
PMCPMC3721335
OpenAlexW2101365115

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.